

**REMARKS/ARGUMENTS**

**Status of the Claims**

Upon entry of the present amendment, claims 18, 25-26, 32, 37-40, 50, 52, 55-59, 61-62, 64, 72-75 and 77-80 are pending. Claims 18, 32, 38, 50, 52, 72, 73, 75 and 77 are amended. New claims 78-80 are added. Claims 1-17, 19-24, 27-31, 33-36, 41-49, 51, 53-54, 60, 63, 65-71 and 76 are canceled without disclaimer or prejudice to renewal. Applicants reserve the right to pursue canceled claims in a continuation or divisional application.

Claim 18 is amended to incorporate the language of canceled claims 19 and 20.

Claims 32, 52 and 73 are amended in accordance with the suggestion of the Examiner to set forth that the antibody binds non-functional P2X<sub>7</sub> receptors but not functional P2X<sub>7</sub> receptors. Support is found, for example, in the abstract, paragraphs [0017], [0040] and [0098].

Claims 38 and 72 are amended in accordance with the suggestion of the Examiner to set forth that the antibody binds non-functional P2X<sub>7</sub> receptors having a sequence in which the proline at amino acid 210 of SEQ ID NO:1 is in the cis conformation, but not functional receptors having a sequence in which proline at amino acid 210 of SEQ ID NO:1 is in the trans conformation. Support is found, for example, in paragraphs [0012] and [0098].

Claim 50 is amended in accordance with the suggestion of the Examiner to set forth a composition further comprising a pharmaceutically acceptable excipient. Support is found, for example, in paragraphs [0049] through [0051].

Claim 52 is amended to set forth topically administering the antibody. Support is found, for example in paragraphs [0041], [0051] and [0104].

Claim 75 is amended for proper antecedent basis.

Claim 77 is amended to depend from a pending claim.

New claims 78-80 find support, for example, in paragraphs [0050] and [104].

No new matter is added by the present amendments, and the Examiner is respectfully requested to enter them.

**Examiner's Amendment**


The Examiner is thanked for calling on August 13, 2007 and proposing an Examiner's Amendment. Applicants do not necessarily agree with the Examiner's position. However, in the interest of furthering prosecution, Applicants have amended the claims.

**CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jennifer L. Wahlsten  
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
JLW:jlw  
61127044 v1